PriceTargets.com logo

Sun BioPharma - SNBP Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 05/3/2024 01:00 AM ET
+0 (0.00%)
Get New Sun BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNBP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNBP

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Sun BioPharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for SNBP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Sun BioPharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/14/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/28/2020Craig HallumInitiated CoverageBuy$9.00
(Data available from 11/12/2019 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/16/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/16/2024
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/15/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/14/2024
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/13/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/13/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/12/2024

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Sun BioPharma

Sun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. Sun BioPharma, Inc. was founded in 2011 and is based in Waconia, Minnesota.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $3.79
Low: $3.45
High: $4.50

52 Week Range

Now: N/A

Volume

49,422 shs

Average Volume

26,926 shs

Market Capitalization

$3.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sun BioPharma?

The following sell-side analysts have issued stock ratings on Sun BioPharma in the last year:
View the latest analyst ratings for SNBP.

What is the current price target for Sun BioPharma?

0 Wall Street analysts have set twelve-month price targets for Sun BioPharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sun BioPharma in the next year.
View the latest price targets for SNBP.

What is the current consensus analyst rating for Sun BioPharma?

Sun BioPharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SNBP.

What other companies compete with Sun BioPharma?

Other companies that are similar to Sun BioPharma include Sol-Gel Technologies, Cadrenal Therapeutics, Tenax Therapeutics, NLS Pharmaceutics and GeoVax Labs. Learn More about companies similar to Sun BioPharma.

How do I contact Sun BioPharma's investor relations team?

Sun BioPharma's physical mailing address is 712 VISTA BLVD 305, WACONIA MN, 55387. The company's listed phone number is 952-479-1196 and its investor relations email address is [email protected]. The official website for Sun BioPharma is www.sunbiopharma.com. Learn More about contacing Sun BioPharma investor relations.